JP6279812B2 - アルドステロンシンターゼ阻害薬 - Google Patents
アルドステロンシンターゼ阻害薬 Download PDFInfo
- Publication number
- JP6279812B2 JP6279812B2 JP2017520427A JP2017520427A JP6279812B2 JP 6279812 B2 JP6279812 B2 JP 6279812B2 JP 2017520427 A JP2017520427 A JP 2017520427A JP 2017520427 A JP2017520427 A JP 2017520427A JP 6279812 B2 JP6279812 B2 JP 6279812B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- optionally substituted
- heterocycle
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CPMQQBRDUAENOJ-UHFFFAOYSA-O CC[SH+]NC(C1CC1)c1cc(C2Oc3cccc(C(N)=O)c3OC2)cnc1 Chemical compound CC[SH+]NC(C1CC1)c1cc(C2Oc3cccc(C(N)=O)c3OC2)cnc1 CPMQQBRDUAENOJ-UHFFFAOYSA-O 0.000 description 1
- PNMADGPAHJEPGI-UHFFFAOYSA-N Cc(c(C1Oc(cccc2C(N)=O)c2OC1)cnc1)c1C#N Chemical compound Cc(c(C1Oc(cccc2C(N)=O)c2OC1)cnc1)c1C#N PNMADGPAHJEPGI-UHFFFAOYSA-N 0.000 description 1
- IQQZIJPWEAFLNT-UHFFFAOYSA-N N#CC1(CC1)c1cc(Br)cnc1 Chemical compound N#CC1(CC1)c1cc(Br)cnc1 IQQZIJPWEAFLNT-UHFFFAOYSA-N 0.000 description 1
- JHQHZWMHKMZLMD-UHFFFAOYSA-N NC(c1cccc2c1OCC(c1cncc(CN(CCC3)C3=O)c1)O2)=O Chemical compound NC(c1cccc2c1OCC(c1cncc(CN(CCC3)C3=O)c1)O2)=O JHQHZWMHKMZLMD-UHFFFAOYSA-N 0.000 description 1
- UOIHFOKNQVWFRH-UHFFFAOYSA-N OC(C(F)(F)F)c1cncc(Br)c1 Chemical compound OC(C(F)(F)F)c1cncc(Br)c1 UOIHFOKNQVWFRH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064234P | 2014-10-15 | 2014-10-15 | |
| US62/064,234 | 2014-10-15 | ||
| PCT/US2015/055421 WO2016061161A1 (en) | 2014-10-15 | 2015-10-14 | Aldosterone synthase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531016A JP2017531016A (ja) | 2017-10-19 |
| JP2017531016A5 JP2017531016A5 (enExample) | 2017-11-30 |
| JP6279812B2 true JP6279812B2 (ja) | 2018-02-14 |
Family
ID=54352516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520427A Active JP6279812B2 (ja) | 2014-10-15 | 2015-10-14 | アルドステロンシンターゼ阻害薬 |
Country Status (33)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9890171B2 (en) * | 2014-12-02 | 2018-02-13 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| EP3562487B1 (en) * | 2016-12-29 | 2023-11-29 | Ji Xing Pharmaceuticals Hong Kong Limited | Metalloenzyme inhibitor compounds |
| JP7530384B2 (ja) | 2019-05-01 | 2024-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート |
| CN116438200A (zh) | 2020-09-10 | 2023-07-14 | 普雷西里克斯公司 | 针对fap的抗体片段 |
| TW202339719A (zh) | 2021-12-14 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療慢性腎臟病之醛固酮合成酶抑制劑 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| JP2025517625A (ja) | 2022-05-02 | 2025-06-10 | プレシリックス・ナームローゼ・ベンノートシヤープ | プレターゲティング |
| CN121181527A (zh) * | 2024-06-21 | 2025-12-23 | 江苏豪森药业集团有限公司 | 双稠环类化合物、及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201026688A (en) * | 2008-10-07 | 2010-07-16 | Schering Corp | Benzodioxan analogues as alpha2C adrenergic receptor modulators |
| JP5659224B2 (ja) * | 2009-05-15 | 2015-01-28 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのアリールピリジン |
| AR088989A1 (es) * | 2011-11-30 | 2014-07-23 | Hoffmann La Roche | Derivados biciclicos de dihidroisoquinolin-1-ona |
| JP6496246B2 (ja) * | 2012-10-05 | 2019-04-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | アルドステロンシンターゼインヒビター関連用途としてのインドリン化合物 |
| BR112015019836A2 (pt) * | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
| JP6067181B2 (ja) * | 2013-04-30 | 2017-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| HUE039981T2 (hu) * | 2014-07-24 | 2019-02-28 | Boehringer Ingelheim Int | Aldoszteron szintáz inhibitorok |
-
2015
- 2015-10-14 CN CN201580053796.XA patent/CN107108587B/zh active Active
- 2015-10-14 NZ NZ729688A patent/NZ729688A/en not_active IP Right Cessation
- 2015-10-14 WO PCT/US2015/055421 patent/WO2016061161A1/en not_active Ceased
- 2015-10-14 US US14/882,486 patent/US9745289B2/en active Active
- 2015-10-14 PE PE2017000710A patent/PE20170696A1/es unknown
- 2015-10-14 AP AP2017009829A patent/AP2017009829A0/en unknown
- 2015-10-14 HU HUE15785014A patent/HUE043783T2/hu unknown
- 2015-10-14 LT LTEP15785014.0T patent/LT3207039T/lt unknown
- 2015-10-14 PL PL15785014T patent/PL3207039T3/pl unknown
- 2015-10-14 ES ES15785014T patent/ES2724555T3/es active Active
- 2015-10-14 DK DK15785014.0T patent/DK3207039T3/en active
- 2015-10-14 AR ARP150103319A patent/AR102266A1/es unknown
- 2015-10-14 KR KR1020177012975A patent/KR102441634B1/ko active Active
- 2015-10-14 CA CA2964754A patent/CA2964754C/en active Active
- 2015-10-14 ME MEP-2019-121A patent/ME03381B/me unknown
- 2015-10-14 MX MX2017004852A patent/MX369025B/es active IP Right Grant
- 2015-10-14 UA UAA201704599A patent/UA118717C2/uk unknown
- 2015-10-14 JP JP2017520427A patent/JP6279812B2/ja active Active
- 2015-10-14 SG SG11201701850UA patent/SG11201701850UA/en unknown
- 2015-10-14 HR HRP20190896TT patent/HRP20190896T1/hr unknown
- 2015-10-14 TW TW104133758A patent/TWI731842B/zh not_active IP Right Cessation
- 2015-10-14 EA EA201790830A patent/EA031766B1/ru not_active IP Right Cessation
- 2015-10-14 EP EP15785014.0A patent/EP3207039B1/en active Active
- 2015-10-14 TR TR2019/07755T patent/TR201907755T4/tr unknown
- 2015-10-14 AU AU2015333611A patent/AU2015333611B2/en not_active Ceased
- 2015-10-14 RS RS20190501A patent/RS58651B1/sr unknown
- 2015-10-14 PT PT15785014T patent/PT3207039T/pt unknown
- 2015-10-14 SI SI201530696T patent/SI3207039T1/sl unknown
-
2017
- 2017-03-15 IL IL251200A patent/IL251200B/en active IP Right Grant
- 2017-03-31 PH PH12017500595A patent/PH12017500595B1/en unknown
- 2017-04-05 CL CL2017000827A patent/CL2017000827A1/es unknown
- 2017-04-05 CO CONC2017/0003305A patent/CO2017003305A2/es unknown
-
2019
- 2019-05-24 CY CY20191100554T patent/CY1121650T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6279812B2 (ja) | アルドステロンシンターゼ阻害薬 | |
| JP6067181B2 (ja) | アルドステロンシンターゼ阻害薬 | |
| AU2012365706B2 (en) | Polycyclic derivatives, preparation method and medical uses thereof | |
| KR102378648B1 (ko) | 알도스테론 신타아제 억제제 | |
| WO2015000412A1 (zh) | 苯并环丁烯类衍生物、其制备方法及其在医药上的应用 | |
| TW202233572A (zh) | 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途 | |
| JP6615896B2 (ja) | アルドステロン合成酵素阻害剤 | |
| JP6707084B2 (ja) | アルドステロンシンターゼ阻害薬 | |
| AU2012323038A1 (en) | 2-oxo-piperidinyl derivatives | |
| JP6914974B2 (ja) | 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体 | |
| BR112017005859B1 (pt) | Inibidores de aldosterona sintase, seus usos e sais farmaceuticamente aceitáveis e composição farmacêutica | |
| HK1243068A1 (en) | Aldosterone synthase inhibitors | |
| HK1243068B (en) | Aldosterone synthase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170414 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170414 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170801 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171220 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180111 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180117 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6279812 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |